7 / 36
Enzalutamide at ADT progression reduced the risk of
disease progression by 56% versus bicalutamide
Bicalutamide
Enzalutamide
HR=0.44
(95% CI: 0.34–0.57)
p=0.0001
56%
RISK REDUCTION
100
0
33
30
27
21
24
18
15
12
9
6
3
0
50
Months
PFS (%)
Enzalutamide, n
184
159
131
107
86
71
52
33
21
13
8
5
Bicalutamide, n
191
133
85
61
44
30
13
7
4
2
2
1
Shore ND, et al. Lancet Oncol 2016